IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
onal Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 2, September 2025 Impact Factor: 7.67

Role of Polymeric Nanocarriers in Advancing Oral Chemotherapy

Tausif Ahmed Khan Saheb Khan[1] and Dr. Ashish Ashok Gawai[2]
[1]Research Scholar, Department of Pharmacy
[2]Professor, Department of Pharmacy
Sunrise University, Alwar, Rajasthan

Abstract: *Oral chemotherapy has emerged as a highly desirable alternative to conventional intravenous cancer treatment due to its convenience, cost-effectiveness, and improved patient compliance. Despite these advantages, the clinical success of oral anticancer drugs is significantly limited by various physiological and biochemical barriers present in the gastrointestinal tract. These include poor aqueous solubility of many chemotherapeutic agents, instability in acidic gastric conditions, enzymatic degradation, limited permeability across intestinal epithelium, and extensive first-pass metabolism in the liver. As a result, many potent anticancer drugs fail to achieve therapeutic concentrations in systemic circulation when administered orally.*

Polymeric nanocarriers have gained considerable attention as an innovative drug delivery system capable of overcoming these limitations. These nanoscale carriers, fabricated from biodegradable and biocompatible polymers, can encapsulate anticancer drugs and protect them from harsh gastrointestinal conditions while enhancing their solubility and absorption. Furthermore, polymeric nanocarriers can be engineered to provide controlled and targeted drug release, thereby minimizing systemic toxicity and improving therapeutic outcomes. Their ability to bypass efflux transporters and enhance cellular uptake makes them particularly promising for oral chemotherapy applications..

Keywords: Polymeric Nanocarriers, Oral Chemotherapy, Drug Delivery Systems

I. INTRODUCTION

Cancer continues to be one of the leading causes of death globally, posing a major challenge to healthcare systems and researchers alike. Conventional chemotherapy, which is primarily administered through intravenous routes, has been widely used for decades in cancer treatment. However, this method is associated with several drawbacks, including systemic toxicity, high treatment costs, the need for hospitalization, and reduced patient compliance due to discomfort and inconvenience. These limitations have prompted researchers to explore alternative drug delivery methods, among which oral chemotherapy has gained significant interest.

Oral chemotherapy offers numerous advantages, such as ease of administration, improved patient comfort, reduced need for medical supervision, and better quality of life. However, its effectiveness is severely hindered by multiple barriers within the gastrointestinal tract. Many anticancer drugs exhibit poor water solubility, making them difficult to absorb in sufficient quantities. Additionally, the acidic environment of the stomach and the presence of digestive enzymes can degrade drugs before they reach systemic circulation. The intestinal epithelium further acts as a barrier, limiting drug permeability, while efflux transporters actively pump drugs back into the intestinal lumen.

To address these challenges, advanced drug delivery systems such as polymeric nanocarriers have been developed. These systems are capable of encapsulating drugs, protecting them from degradation, and facilitating their transport across biological barriers. By improving bioavailability and enabling targeted delivery, polymeric nanocarriers have the potential to significantly enhance the efficacy of oral chemotherapy. This paper aims to provide a comprehensive overview of these systems and their role in modern cancer treatment.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 2, September 2025 Impact Factor: 7.67

CHALLENGES IN ORAL CHEMOTHERAPY

Oral chemotherapy faces numerous challenges that limit its clinical effectiveness and widespread application. One of the primary obstacles is the poor aqueous solubility of many anticancer drugs. Since drugs must dissolve in gastrointestinal fluids before absorption, low solubility results in inadequate drug availability for systemic circulation. This issue is particularly significant for hydrophobic drugs, which constitute a large proportion of chemotherapeutic agents.

Another major challenge is the instability of drugs in the gastrointestinal environment. The stomach's acidic pH and digestive enzymes can degrade sensitive drug molecules, reducing their therapeutic efficacy. Additionally, the intestinal epithelium acts as a selective barrier that restricts the absorption of large or hydrophilic molecules. Tight junctions between epithelial cells further limit paracellular transport, making it difficult for drugs to penetrate the intestinal lining.

Efflux transporters, such as P-glycoprotein, present another significant hurdle by actively pumping drugs back into the intestinal lumen, thereby reducing their intracellular concentration. Furthermore, drugs that are successfully absorbed often undergo extensive first-pass metabolism in the liver, where they are chemically modified and inactivated before reaching systemic circulation.

These combined barriers result in low bioavailability, inconsistent drug absorption, and reduced therapeutic outcomes. Consequently, higher doses are often required, which increases the risk of systemic toxicity and adverse side effects. Addressing these challenges is crucial for the successful development of effective oral chemotherapy systems. Polymeric nanocarriers provide a promising solution by enhancing drug stability, solubility, and absorption while minimizing degradation and metabolic loss.

POLYMERIC NANOCARRIERS: OVERVIEW

Polymeric nanocarriers are nanoscale drug delivery systems composed of natural or synthetic polymers that are designed to transport therapeutic agents to specific sites in the body. These carriers typically range in size from 10 to 1000 nanometers and can be engineered to possess unique physicochemical properties that enhance drug delivery. Commonly used polymers include poly (lactic-co-glycolic acid) (PLGA), chitosan, polyethylene glycol (PEG), and polycaprolactone (PCL), all of which are known for their biocompatibility and biodegradability.

These nanocarriers can take various structural forms, including nanoparticles, micelles, dendrimers, and hydrogels. Each type has distinct characteristics that make it suitable for specific applications. For instance, polymeric nanoparticles provide excellent stability and controlled drug release, while micelles are particularly effective for delivering hydrophobic drugs due to their core-shell structure. Dendrimers offer precise molecular architecture and high drug-loading capacity, whereas hydrogels are known for their ability to retain large amounts of water and provide sustained drug release.

One of the key advantages of polymeric nanocarriers is their ability to protect encapsulated drugs from degradation in the gastrointestinal tract. Additionally, their surface can be modified with targeting ligands or hydrophilic polymers to enhance absorption and reduce immune recognition. This versatility allows researchers to tailor nanocarriers according to specific therapeutic needs.

Overall, polymeric nanocarriers represent a highly adaptable and efficient drug delivery platform that can address many of the limitations associated with oral chemotherapy, making them a focal point of current pharmaceutical research.

TYPES OF POLYMERIC NANOCARRIERS

Type	Description	Advantages	Limitations
Polymeric Nanoparticles	Solid particles with drug encapsulated or adsorbed	Controlled release, high stability	Complex synthesis
Micelles	Amphiphilic structures with hydrophobic core	Good for poorly soluble drugs	Instability in vivo

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
onal Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 2, September 2025 Impact Factor: 7.67

Dendrimers	Branched polymers with defined structure	High drug loading	Possible toxicity
Hydrogels	Water-swollen polymer networks	Sustained release	Weak mechanical strength

MECHANISMS OF ACTION

Polymeric nanocarriers enhance oral chemotherapy through multiple mechanisms that improve drug delivery and therapeutic efficacy. One of the primary mechanisms is the protection of drugs from degradation. By encapsulating drugs within a polymeric matrix, nanocarriers shield them from the acidic environment of the stomach and enzymatic activity in the gastrointestinal tract. This ensures that a larger proportion of the drug remains intact and available for absorption.

Another important mechanism is the enhancement of drug solubility. Many anticancer drugs are hydrophobic in nature and exhibit poor solubility in aqueous environments. Polymeric nanocarriers can incorporate these drugs into their structure, thereby increasing their apparent solubility and facilitating their dissolution in gastrointestinal fluids.

Nanocarriers also improve drug absorption by promoting interaction with the intestinal epithelium. Surface modification techniques, such as PEGylation or ligand attachment, can enhance mucoadhesion and facilitate transport across biological membranes. Additionally, some nanocarriers can bypass efflux transporters, allowing drugs to remain داخل cells for longer durations.

Controlled and sustained drug release is another key feature of polymeric nanocarriers. By adjusting polymer composition and structure, drug release can be regulated over time, reducing dosing frequency and minimizing side effects. Furthermore, targeted delivery can be achieved by attaching specific ligands to the nanocarrier surface, enabling selective accumulation in tumor tissues.

These combined mechanisms significantly improve the bioavailability and therapeutic effectiveness of oral chemotherapy drugs.

ADVANTAGES

Polymeric nanocarriers offer numerous advantages that make them highly suitable for oral chemotherapy applications. One of the most significant benefits is the enhancement of drug bioavailability. By improving solubility, stability, and absorption, nanocarriers ensure that a greater proportion of the administered drug reaches systemic circulation. This leads to improved therapeutic outcomes and reduced variability in drug response.

Another major advantage is the reduction of systemic toxicity. Conventional chemotherapy often affects healthy cells along with cancerous ones, leading to severe side effects. Polymeric nanocarriers enable targeted drug delivery, ensuring that drugs are preferentially accumulated in tumor tissues while minimizing exposure to healthy cells. This selective targeting significantly reduces adverse effects and improves patient safety.

Improved patient compliance is another important benefit. Oral chemotherapy eliminates the need for frequent hospital visits and invasive procedures, making treatment more convenient and less stressful for patients. Additionally, controlled and sustained drug release reduces the frequency of dosing, further enhancing compliance.

Polymeric nanocarriers also provide flexibility in drug formulation. Their properties can be tailored to meet specific therapeutic requirements, such as pH sensitivity, temperature responsiveness, or targeted delivery. This adaptability makes them suitable for a wide range of anticancer drugs.

Overall, the use of polymeric nanocarriers in oral chemotherapy represents a significant advancement in drug delivery technology, offering improved efficacy, safety, and patient convenience.

LIMITATIONS AND FUTURE PERSPECTIVES

Despite their numerous advantages, polymeric nanocarriers also face several limitations that must be addressed before their widespread clinical application. One of the primary challenges is the complexity of their design and

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
onal Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 2, September 2025 Impact Factor: 7.67

manufacturing. Producing nanocarriers with consistent size, shape, and drug-loading efficiency requires sophisticated techniques and strict quality control measures, which can increase production costs.

Stability during storage is another concern. Nanocarriers may undergo aggregation or degradation over time, affecting their performance and shelf life. Additionally, there are potential safety concerns related to long-term toxicity and accumulation of polymers in the body. Although many polymers used are biodegradable, their degradation products must be carefully evaluated for safety.

Regulatory challenges also pose a significant barrier to the commercialization of polymeric nanocarriers. Due to their complex nature, these systems require extensive testing to ensure safety, efficacy, and reproducibility. This can delay approval processes and increase development costs.

Looking forward, ongoing research is focused on developing advanced nanocarriers with improved functionality, such as stimuli-responsive systems that release drugs in response to specific environmental triggers. Integration with personalized medicine and artificial intelligence may further enhance the effectiveness of oral chemotherapy.

While challenges remain, polymeric nanocarriers hold immense potential to revolutionize oral chemotherapy and improve cancer treatment outcomes in the future.

II. CONCLUSION

The role of polymeric nanocarriers in advancing oral chemotherapy represents a significant breakthrough in the field of cancer drug delivery, offering promising solutions to many of the limitations associated with conventional treatment approaches. Oral chemotherapy has long been considered an ideal alternative to intravenous administration due to its convenience, cost-effectiveness, and ability to improve patient compliance and quality of life. However, its clinical success has been restricted by numerous physiological barriers, including poor drug solubility, instability in the gastrointestinal environment, limited permeability across intestinal membranes, and extensive first-pass metabolism.

These challenges have historically resulted in low bioavailability and inconsistent therapeutic outcomes, thereby limiting the widespread adoption of oral anticancer therapies. In this context, polymeric nanocarriers have emerged as an innovative and highly adaptable platform capable of overcoming these barriers and enhancing the efficiency of oral drug delivery systems.

Polymeric nanocarriers, developed using biodegradable and biocompatible polymers such as PLGA, chitosan, PEG, and PCL, provide multiple functional advantages that collectively improve the pharmacokinetic and pharmacodynamic profiles of anticancer drugs. By encapsulating therapeutic agents within a polymeric matrix, these nanocarriers protect drugs from degradation caused by acidic pH and enzymatic activity in the gastrointestinal tract. Furthermore, their ability to enhance the solubility of poorly water-soluble drugs significantly improves dissolution and absorption. Surface modifications, including PEGylation and ligand conjugation, enable improved mucoadhesion, prolonged circulation time, and targeted delivery to tumor tissues. This targeted approach not only increases drug concentration at the desired site but also minimizes exposure to healthy tissues, thereby reducing systemic toxicity and adverse side effects commonly associated with chemotherapy.

In addition to improving drug stability and targeting, polymeric nanocarriers offer controlled and sustained release mechanisms, allowing drugs to be released at a predetermined rate over an extended period. This feature reduces the frequency of dosing and ensures a more consistent therapeutic effect, which is particularly beneficial for chronic cancer treatment. Moreover, the versatility of polymeric nanocarriers allows for the incorporation of multiple therapeutic agents, opening avenues for combination therapy and synergistic treatment strategies. Advances in nanotechnology have also led to the development of stimuli-responsive nanocarriers that can release drugs in response to specific environmental triggers such as pH, temperature, or enzymatic activity, further enhancing precision in drug delivery.

Despite these advantages, certain challenges remain that must be addressed to fully realize the clinical potential of polymeric nanocarriers in oral chemotherapy. Issues related to large-scale manufacturing, stability during storage, reproducibility, and regulatory approval continue to pose obstacles. Additionally, concerns regarding long-term toxicity, immunogenicity, and the accumulation of polymer residues in the body require thorough investigation.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 2, September 2025 Impact Factor: 7.67

Addressing these challenges will require interdisciplinary collaboration among researchers, clinicians, and regulatory agencies, as well as continued advancements in material science and nanotechnology.

Polymeric nanocarriers hold immense potential to transform oral chemotherapy by overcoming traditional barriers and significantly enhancing drug delivery efficiency. Their ability to improve bioavailability, enable targeted and controlled drug release, and reduce systemic toxicity positions them as a cornerstone of next-generation cancer therapies. With ongoing research and technological innovation, polymeric nanocarriers are expected to play a crucial role in the future of personalized medicine, ultimately leading to more effective, safer, and patient-friendly cancer treatment strategies.

REFERENCES

[1]. Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008). Factors affecting the clearance of nanoparticles. *Molecular Pharmaceutics, 5*(4), 505–515. https://doi.org/10.1021/mp800051m

[2]. Bae, Y., & Park, K. (2011). Targeted drug delivery to tumors. *Journal of Controlled Release, 153*(3), 198–205. https://doi.org/10.1016/j.jconrel.2011.06.001

[3]. Blanco, E., Shen, H., & Ferrari, M. (2015). Principles of nanoparticle design. *Nature Biotechnology, 33*(9), 941–951. https://doi.org/10.1038/nbt.3330

[4]. Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V. (2012). PLGA-based nanoparticles: An overview of biomedical applications. *Journal of Controlled Release, 161*(2), 505–522. https://doi.org/10.1016/j.jconrel.2012.01.043

[5]. des Rieux, A., Fievez, V., Garinot, M., Schneider, Y. J., & Préat, V. (2006). Nanoparticles as potential oral delivery systems. *Journal of Controlled Release, 116*(1), 1–27. https://doi.org/10.1016/j.jconrel.2006.08.013

[6]. Duncan, R. (2003). The dawning era of polymer therapeutics. *Nature Reviews Drug Discovery, 2*(5), 347–360. https://doi.org/10.1038/nrd1088

[7]. Farokhzad, O. C., & Langer, R. (2009). Impact of nanotechnology on drug delivery. *ACS Nano, 3*(1), 16–20. https://doi.org/10.1021/nn900002m

[8]. Koo, H., Huh, M. S., Sun, I. C., Yuk, S. H., Choi, K., Kim, K., & Kwon, I. C. (2011). In vivo targeted delivery of nanoparticles for theranosis. *Accounts of Chemical Research, 44*(10), 1018–1028. https://doi.org/10.1021/ar2000369

[9]. Kumari, A., Yadav, S. K., & Yadav, S. C. (2010). Biodegradable polymeric nanoparticles-based drug delivery systems. *Colloids and Surfaces B: Biointerfaces, 75*(1), 1–18. https://doi.org/10.1016/j.colsurfb.2009.09.001

[10]. Kwon, G. S., & Kataoka, K. (1995). Block copolymer micelles as drug carriers. *Advanced Drug Delivery Reviews, 16*(2–3), 295–309. https://doi.org/10.1016/0169-409X(95)00017-8

[11]. Mitragotri, S., Burke, P. A., & Langer, R. (2014). Overcoming challenges in drug delivery. *Nature Reviews Drug Discovery, 13*(9), 655–672. https://doi.org/10.1038/nrd4363

[12]. Muthu, M. S., Leong, D. T., Mei, L., & Feng, S. S. (2014). Nanotheranostics for cancer treatment. *Theranostics, 4*(6), 660–677. https://doi.org/10.7150/thno.8694

[13]. Parveen, S., Misra, R., & Sahoo, S. K. (2012). Nanoparticles: A boon to drug delivery. *Nanomedicine, 8*(2), 147–166. https://doi.org/10.1016/j.nano.2011.05.016

[14]. Patel, A., Cholkar, K., Agrahari, V., & Mitra, A. K. (2018). Ocular drug delivery systems: An overview. *World Journal of Pharmacology, 7*(1), 1–12. https://doi.org/10.5497/wjp.v7.i1.1

[15]. Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007). Nanocarriers as emerging platforms for cancer therapy. *Nature Nanotechnology, 2*(12), 751–760. https://doi.org/10.1038/nnano.2007.387

[16]. Singh, R., & Lillard, J. W. (2009). Nanoparticle-based targeted drug delivery. *Experimental and Molecular Pathology, 86*(3), 215–223. https://doi.org/10.1016/j.yexmp.2008.12.004

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
onal Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 2, September 2025 Impact Factor: 7.67

[17]. Sinha, R., Kim, G. J., Nie, S., & Shin, D. M. (2006). Nanotechnology in cancer therapeutics. *Molecular Cancer Therapeutics, 5*(8), 1909–1917. https://doi.org/10.1158/1535-7163.MCT-06-0141

[18]. Torchilin, V. P. (2007). Micellar nanocarriers: Pharmaceutical perspectives. *Pharmacological Research, 55*(6), 585–591. https://doi.org/10.1016/j.phrs.2007.04.003

[19]. Wang, J., Mongayt, D., & Torchilin, V. P. (2005). Polymeric micelles for delivery of poorly soluble drugs. *Journal of Drug Targeting, 13*(2), 73–80. https://doi.org/10.1080/10611860500034375

[20]. Zhang, L., Gu, F. X., Chan, J. M., Wang, A. Z., Langer, R. S., & Farokhzad, O. C. (2008). Nanoparticles in medicine: Therapeutic applications. *Clinical Pharmacology & Therapeutics, 83*(5), 761–769. https://doi.org/10.1038/clpt.2008.16